Evidence map›Paper›PMID 37311127›Full record

ArticleArquivos brasileiros de cardiologia2023

Prognostic Value of Non-HDL Cholesterol in COVID-19 Pneumonia.

Fatih Sivri, Mehtap Şencan, Şerife Barçın Öztürk, Ayşe Sema Maraşlı, Yahya Kemal İçen, Çağdaş Akgüllü

Open access · diamondAbstract read
In one paragraph

Article in Arquivos brasileiros de cardiologia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Fatih SivriDortyol State Hospital, Hatay - Turquia.ORCID 0000-0003-1998-361X
Mehtap ŞencanDortyol State Hospital, Hatay - Turquia.ORCID 0000-0001-8134-9965
Şerife Barçın ÖztürkAdnan Menderes University, Aydın - Turquia.ORCID 0000-0003-3756-8276
Ayşe Sema MaraşlıDortyol State Hospital, Hatay - Turquia.ORCID 0000-0002-7456-3610
Yahya Kemal İçenAdana Health Practice and Research Center, Adana - Turquia.ORCID 0000-0003-0070-5281
Çağdaş AkgüllüAdnan Menderes University, Aydın - Turquia.ORCID 0000-0003-4978-1955
State Hospital · GBAdnan Menderes University · TRAdana Science and Technology University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn addition to coronary artery disease, non-high-density lipoprotein(non-HDL-C) provides short and long-term predictive information for many chronic inflammatory diseases such as stroke, hemodialysis, post-renal transplant, non-alcoholic hepatosteatosis, and human immunodeficiency virus.

objectivesThis study examined the predictive value of non-HDL-C measured before SARS-CoV-2 for mortality in COVID-19 infection.

methodsThis study retrospectively included 1435 patients diagnosed with COVID-19 and treated in the thoracic diseases ward in a single center between January 2020 and June 2022. All patients included in the study had clinical and radiological features and signs of COVID-19 pneumonia. The COVID-19 diagnosis of all patients was confirmed by a polymerase chain reaction studied from an oropharyngeal swab. Statistical significance was set at p < 0.05.

resultsThe study patients, including 1435 subjects, were divided into 712 patients in the non-surviving group and 723 in the surviving group. While there was no difference between the groups regarding gender, there was a statistically significant age difference. The non-surviving group was older. Age, lactate dehydrogenase(LDH), C reactive protein(CRP), triglycerides, D-dimer, and non-HDL-C were independent risk factors for mortality in regression analyses. In correlation analysis, age, CRP, and LDH were positively correlated with non-HDL-C. In the ROC analysis, sensitivity for non-HDL-C was 61.6%, and specificity was 89.2%.

conclusionWe believe that the non-HDL-C level studied before COVID-19 infection can be used as a prognostic biomarker for the disease.

Indexed as

COVID-19CholesterolCOVID-19 TestingHumansLipoproteinsPrognosisRetrospective StudiesSARS-CoV-2CholesterolLipoproteins

Identifiers

PMID37311127
PMCPMC10263406
OpenAlexW4379232503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.